Case Study: Swiss Biopharmaceutical Company accelerates Brazil BLA approval with FREYR regulatory support

Swiss Biopharmaceutical Company advances Brazil BLA with FREYR and zero GMP resubmissions

A Swiss biopharmaceutical company faced the complex challenge of registering a monoclonal antibody product in Brazil, requiring navigation of ANVISA's full BLA pathway. With evolving regulatory requirements and no local presence, the client needed a partner to manage three critical, interdependent workstreams simultaneously: documentation alignment, cold chain validation, and GMP certification review. They engaged FREYR for end-to-end regulatory support and operations.

FREYR initiated the engagement with a detailed gap analysis and managed all workstreams in parallel, including pre-submission agency engagement and direct liaison with ANVISA. This comprehensive approach resulted in full compliance, zero resubmissions for the GMP certification, and a materially reduced time to market for the client's product.